Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Application (Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases), Route of Administration - Global Forecast 2024-2030
The Antisense & RNAi Therapeutics Market size was estimated at USD 4.51 billion in 2023 and expected to reach USD 4.93 billion in 2024, at a CAGR 9.34% to reach USD 8.43 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antisense & RNAi Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antisense & RNAi Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Axolabs GmbH, Benitec Biopharma Limited, BioNTech SE, Carisma Therapeutics Inc., Dicerna Pharmaceuticals, Inc., Evox Therapeutics Ltd, Exicure, Inc., GenScript Biotech Corporation, InteRNA Technologies BV, Ionis Pharmaceuticals, Inc., miRagen Therapeutics, Inc., Regenxbio Inc., RXi Pharmaceuticals Corporation, Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., and Wave Life Sciences Ltd.
Market Segmentation & Coverage
This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Technology
Antisense RNA
miRNA
Cardiovascular Diseases (CVDs)
Intra-dermal Injections
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Antisense & RNAi Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antisense & RNAi Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Antisense & RNAi Therapeutics Market?
- What is the market share of the leading vendors in the Antisense & RNAi Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Antisense & RNAi Therapeutics Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Antisense & RNAi Therapeutics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increase in geriatric populations and prevalence of chronic diseases worldwide
- 5.1.1.2. Growing need for effective and novel therapeutics
- 5.1.1.3. Increase in R&D activities on antisense and RNAi-based therapies
- 5.1.2. Restraints
- 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
- 5.1.3. Opportunities
- 5.1.3.1. Clinical advancements in antisense-RNAi-therapeutics
- 5.1.3.2. Significant investments in the discovery and development of antisense-RNAi-therapeutics
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Antisense & RNAi Therapeutics Market, by Technology
- 6.1. Introduction
- 6.2. Antisense RNA
- 6.3. RNA Interference
- 6.4.1. miRNA
- 6.4.2. siRNA
- 7. Antisense & RNAi Therapeutics Market, by Application
- 7.1. Introduction
- 7.2. Cardiovascular Diseases (CVDs)
- 7.3. Genetic Disorders
- 7.4. Infectious Diseases
- 7.5. Neurodegenerative Disorders
- 7.6. Oncology
- 7.7. Renal Diseases
- 7.8. Respiratory Disorders
- 8. Antisense & RNAi Therapeutics Market, by Route of Administration
- 8.1. Introduction
- 8.2. Intra-dermal Injections
- 8.3. Intraperitoneal Injections
- 8.4. Intravenous Injections
- 8.5. Pulmonary Delivery
- 8.6. Topical Delivery
- 9. Americas Antisense & RNAi Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Antisense & RNAi Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Alnylam Pharmaceuticals, Inc.
- 13.1.2. Amarna Therapeutics BV
- 13.1.3. Arbutus Biopharma Corporation
- 13.1.4. Arrowhead Pharmaceuticals, Inc.
- 13.1.5. AstraZeneca plc
- 13.1.6. Axolabs GmbH
- 13.1.7. Benitec Biopharma Limited
- 13.1.8. BioNTech SE
- 13.1.9. Carisma Therapeutics Inc.
- 13.1.10. Dicerna Pharmaceuticals, Inc.
- 13.1.11. Evox Therapeutics Ltd
- 13.1.12. Exicure, Inc.
- 13.1.13. GenScript Biotech Corporation
- 13.1.14. InteRNA Technologies BV
- 13.1.15. Ionis Pharmaceuticals, Inc.
- 13.1.16. miRagen Therapeutics, Inc.
- 13.1.17. Regenxbio Inc.
- 13.1.18. RXi Pharmaceuticals Corporation
- 13.1.19. Sanofi S.A.
- 13.1.20. Silence Therapeutics plc
- 13.1.21. Sirnaomics, Inc.
- 13.1.22. Wave Life Sciences Ltd
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTISENSE & RNAI THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
- FIGURE 8. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 12. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook